These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 29653234)

  • 21. High blood eosinophil counts predict sputum eosinophilia in patients with severe asthma.
    Fowler SJ; Tavernier G; Niven R
    J Allergy Clin Immunol; 2015 Mar; 135(3):822-4.e2. PubMed ID: 25445828
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthma.
    Lim HF; Nair P
    Expert Rev Respir Med; 2015 Apr; 9(2):135-42. PubMed ID: 25578680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A case of chronic eosinophilic pneumonia successfully treated with mepolizumab.
    To M; Kono Y; Yamawaki S; Soeda S; Katsube O; Kishi H; To Y
    J Allergy Clin Immunol Pract; 2018; 6(5):1746-1748.e1. PubMed ID: 30201098
    [No Abstract]   [Full Text] [Related]  

  • 24. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.
    Khatri S; Moore W; Gibson PG; Leigh R; Bourdin A; Maspero J; Barros M; Buhl R; Howarth P; Albers FC; Bradford ES; Gilson M; Price RG; Yancey SW; Ortega H
    J Allergy Clin Immunol; 2019 May; 143(5):1742-1751.e7. PubMed ID: 30359681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Controversies in Allergy: Should Severe Asthma with Eosinophilic Phenotype Always Be Treated with Anti-IL-5 Therapies.
    Pavord ID; Hanania NA
    J Allergy Clin Immunol Pract; 2019; 7(5):1430-1436. PubMed ID: 30962155
    [No Abstract]   [Full Text] [Related]  

  • 26. Biomarkers for severe eosinophilic asthma.
    Yancey SW; Keene ON; Albers FC; Ortega H; Bates S; Bleecker ER; Pavord I
    J Allergy Clin Immunol; 2017 Dec; 140(6):1509-1518. PubMed ID: 29221581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vedolizumab Treatment May Reduce Steroid Burden and Improve Histology in Patients With Eosinophilic Gastroenteritis.
    Kim HP; Reed CC; Herfarth HH; Dellon ES
    Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1992-1994. PubMed ID: 29596982
    [No Abstract]   [Full Text] [Related]  

  • 28. A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting.
    Cameli P; Bergantini L; d'Alessandro M; Perruzza M; Cekorja B; Perillo F; Massa E; Ruzza A; Fossi A; Beltrami V; Sestini P; Bargagli E
    Int Arch Allergy Immunol; 2020; 181(8):606-612. PubMed ID: 32516771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severe Eosinophilic Allergic Asthma Responsive to Mepolizumab After Failure of 2 Consecutive Biologics.
    Sánchez-Jareño M; Barranco P; Romero D; Domínguez-Ortega J; Quirce S
    J Investig Allergol Clin Immunol; 2019 Feb; 29(1):79-81. PubMed ID: 30785114
    [No Abstract]   [Full Text] [Related]  

  • 30. Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one center's early clinical experience.
    Weir E; Paton J
    J Asthma; 2020 May; 57(5):521-524. PubMed ID: 30795693
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma.
    Tajiri T; Matsumoto H; Hiraumi H; Ikeda H; Morita K; Izuhara K; Ono J; Ohta S; Ito I; Oguma T; Nakaji H; Inoue H; Iwata T; Nagasaki T; Kanemitsu Y; Ito J; Niimi A; Mishima M
    Ann Allergy Asthma Immunol; 2013 May; 110(5):387-8. PubMed ID: 23622013
    [No Abstract]   [Full Text] [Related]  

  • 32. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study.
    Lugogo N; Domingo C; Chanez P; Leigh R; Gilson MJ; Price RG; Yancey SW; Ortega HG
    Clin Ther; 2016 Sep; 38(9):2058-2070.e1. PubMed ID: 27553751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma.
    Katz LE; Gleich GJ; Hartley BF; Yancey SW; Ortega HG
    Ann Am Thorac Soc; 2014 May; 11(4):531-6. PubMed ID: 24606022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. May mepolizumab used in asthma correct subfertility?
    Ozden G; Pınar Deniz P
    Ann Med; 2021 Dec; 53(1):456-458. PubMed ID: 33739210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reslizumab as add-on therapy in patients with refractory asthma.
    Virchow JC; McDonald M; Garin M; Korn S
    BMJ Open Respir Res; 2020 Apr; 7(1):. PubMed ID: 32273395
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment of hypereosinophilic syndrome and eosinophilic dermatitis with reslizumab.
    Kuruvilla M
    Ann Allergy Asthma Immunol; 2018 Jun; 120(6):670-671. PubMed ID: 29496465
    [No Abstract]   [Full Text] [Related]  

  • 37. Reslizumab in the treatment of severe eosinophilic asthma: an update.
    Walsh GM
    Immunotherapy; 2018 Jun; 10(8):695-698. PubMed ID: 29554826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current update on eosinophilic lung diseases and anti-IL-5 treatment.
    Samitas K; Rådinger M; Bossios A
    Recent Pat Antiinfect Drug Discov; 2011 Sep; 6(3):189-205. PubMed ID: 21824072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Severe uncontrolled eosinophilic asthma, which responded to benralizumab after failure to respond to mepolizumab.
    Kurosawa M; Sutoh E
    Ann Allergy Asthma Immunol; 2019 Apr; 122(4):431-433. PubMed ID: 30578859
    [No Abstract]   [Full Text] [Related]  

  • 40. [Severe refractory eosinophilic asthma].
    Jäger-Becker D
    MMW Fortschr Med; 2016 Feb; 158(3):67. PubMed ID: 27119709
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.